You might also like
Maravai LifeSciences Holdings, Inc. (MRVI) is a leading life sciences company that provides essential products to support the development of vaccines, drug therapies, diagnostics, and research on human diseases. The company serves global biopharmaceutical firms, emerging research companies, academic institutions, and diagnostics companies. MRVI specializes in manufacturing complex nucleic acids, custom enzymes, and antibody-based products for biopharmaceutical development and biologics safety testing.
-
Nucleic Acid Production - Manufactures highly modified nucleic acids for research, therapeutic, and vaccine programs, including mRNA products and CleanCap® technology for stabilizing mRNA.
- Sub-products: Plasmid DNA products used as templates for mRNA production.
-
Biologics Safety Testing - Produces host cell protein detection kits, bioprocess impurity detection kits, viral clearance prediction kits, and related products to ensure the safety of biologic drug manufacturing.
- Services: Custom antibody development, assay development, and mass spectrometry for biologic drug production.
Name | Position | External Roles | Short Bio | |
---|---|---|---|---|
Christine Dolan Executive | Executive Vice President and General Manager, Cygnus Technologies | Christine Dolan currently serves as Executive Vice President and General Manager, Cygnus Technologies at MRVI since January 1, 2024. Previously, she served as Chief Operating Officer, Biologics Safety Testing from October 2017 to December 2023. | ||
Kevin Herde Executive | Chief Financial Officer (CFO) | Kevin Herde is the Chief Financial Officer (CFO) of Maravai LifeSciences Holdings, Inc. since May 2017. He brings over 25 years of experience in finance, accounting, and general management, previously serving as the CFO at Sorrento Therapeutics from April 2016 to May 2017. | ||
Kurt Oreshack Executive | Executive Vice President, General Counsel, and Secretary | Kurt Oreshack has served as Executive Vice President, General Counsel, and Secretary at Maravai LifeSciences Holdings, Inc. since November 2020, overseeing legal and corporate governance matters. Previously, he held roles including Partner at Breakwater Law Group, LLP and General Counsel at Human Longevity, Inc., which bolstered his expertise in corporate law and regulatory compliance. | ||
Peter Leddy Executive | Chief Administrative Officer | Peter Leddy has served as the Chief Administrative Officer at MRVI since June 27, 2022, overseeing HR, DEI, ESG, facilities, and security functions. He has extensive prior experience in executive HR roles at companies including Life Technologies and Aloisio Partners. | ||
Rebecca Buzzeo Executive | Executive Vice President and Chief Commercial Officer | Rebecca Buzzeo is the Executive Vice President and Chief Commercial Officer at MRVI since November 6, 2023. Previously, she served as Senior Vice President, Chief Commercial Officer and Chief Operating Officer, Nucleic Acid Services from October 17, 2022 to November 5, 2023. | ||
William E. Martin Executive | Chief Executive Officer | William E. Martin, III is the Chief Executive Officer of MRVI since July 27, 2023. He previously served as CEO for a brief period from September 30, 2022 to October 18, 2022 and as President of the Biologics Safety Testing division from December 5, 2022 until his reappointment as CEO. | View Report → | |
Benjamin Daverman Board | Director | Managing Director and Co-Head of the Healthcare Group at GTCR | Benjamin Daverman has been serving as a Director at MRVI since November 2020. Previously, he served on the Compensation and Nominating Committee until October 2022 and has extensive experience in healthcare and life sciences, including his current role as Managing Director and Co-Head of the Healthcare Group at GTCR. | |
Constantine Mihas Board | Board Member | Co-CEO and Managing Director at GTCR; Board Member of Sotera Health Company | Constantine Mihas is an experienced leader in the healthcare, pharmaceutical, and life sciences industries. He has served on the Board of Directors at MRVI since November 2020 and previously chaired the Compensation and Nominating Committee until October 2022. | |
Gregory T. Lucier Board | Director on the Board | Director at Catalent; Director at Dentsply Sirona Inc. | Gregory T. Lucier has been a Director on the Board of MRVI since November 2020, bringing over 30 years of leadership experience in the healthcare and life sciences sectors, with previous roles including CEO at Corza Health, Inc. and NuVasive, Inc. | |
Jessica Hopfield Board | Board Member | Independent Director at Insulet Corporation; Independent Director at Editas Medicine | Jessica Hopfield, Ph.D., is a seasoned leader in the life sciences industry, serving as a Board Member at MRVI since November 2020 and as Chair of the Nominating, Governance, and Risk Committee since October 2022. She has over two decades of experience and has held independent director roles at companies such as Insulet Corporation and Editas Medicine. | |
John DeFord Board | Director | Board of Directors, Nordson Corporation; Board of Directors, Globus Medical Inc. | John DeFord, PhD, is a seasoned leader in the healthcare and medical device sectors, currently serving as a Director at MRVI since July 20, 2023. He has held key executive and board roles in other companies such as Nordson Corporation and Globus Medical Inc.. | |
Luke Marker Board | Board of Directors | Managing Director at GTCR | Luke Marker has served on the Board of Directors at MRVI since November 2020 and been a member of MLSH 1’s board since 2016. He is currently a Managing Director at GTCR since 2009 and has previous experience in investment banking at Lehman Brothers and Barclays Capital. | |
Murali K. Prahalad Board | Director | President and Chief Executive Officer at Iridia, Inc. | Dr. Prahalad has been serving as a Director on the Board of MRVI since November 2020. He also leads Iridia, Inc. as President and Chief Executive Officer since November 2019. | |
Robert Andrew Eckert Board | Chairman of the Board | Chairman of Kipu Health; Lead Director at Fortrea; Director at Becton, Dickinson and Company | Robert Andrew Eckert has extensive leadership experience across the healthcare and life sciences sectors, having served as CEO at multiple companies prior to his appointment as Chairman of the Board at MRVI on December 5, 2024. His prior roles include CEO positions at ADAC Laboratories, SumTotal Systems, and several others. | |
Sean Cunningham Board | Director | Board of Directors of Sotera Health; Managing Director and Co-Head of the Healthcare Group at GTCR | Sean Cunningham has served as a Director on the Board of Directors of MRVI since November 2020. He is also a member of the Nominating, Governance and Risk Committee since October 2022 and holds active roles outside MRVI, including as a Managing Director and Co-Head of the Healthcare Group at GTCR and as a Board Director at Sotera Health. | |
Susannah Gray Board | Director | Director at 4D Molecular Therapeutics, Inc.; Director at Morphic Holding, Inc.; Director at Theravance Biopharma, Inc. | Susannah Gray has served as a Director at MRVI since November 2020, acting as Chair of the Audit Committee and as a member of the Compensation and Leadership Development Committee. Previously, she served as CFO and later EVP at Royalty Pharma, and held senior roles at CIBC World Markets and Merrill Lynch. |
- Given the challenges in forecasting due to dynamic movements in customer programs, how confident are you in your ability to improve visibility into your pipeline, and what specific measures are you implementing to ensure more accurate financial guidance?
- With your cost structure remaining around $200 million, what strategic rationale supports maintaining such high fixed costs in the face of declining revenues, and what levers can you pull if market conditions worsen further?
- Given the significant decline in your base Nucleic Acid Production revenues, down about 20% for the year and close to 30% in the fourth quarter, what makes you confident that this business is stabilizing in 2025, and what are the key drivers for a potential turnaround?
- How are you factoring in potential headwinds from changes at NIH and FDA affecting academic and biotech customer spending into your 2025 guidance, and what are your assumptions regarding growth prospects in China amid the current geopolitical climate?
- Following your significant voluntary debt repayment and with current financial constraints, how are you prioritizing capital allocation between potential M&A opportunities, investment in organic growth, and further debt reduction?
Competitors mentioned in the company's latest 10K filing.
Company | Description |
---|---|
For mRNA capping analogs, they offer alternatives to CleanCap with enzymatic capping solutions. They also serve less complex customer needs in the custom oligonucleotide space and compete in the oligonucleotide synthesis inputs market as large distributor-manufacturers. | |
Aldevron (a subsidiary of Danaher) | They offer alternatives to CleanCap with enzymatic capping solutions for mRNA capping analogs and compete in the mRNA offerings market. |
New England Biolabs | They offer alternatives to CleanCap with enzymatic capping solutions for mRNA capping analogs and compete in the specialty enzymes offering. |
Patheon | They compete in the mRNA offerings market. |
eTheRNA | They compete in the mRNA offerings market. |
Lonza | They compete in the mRNA offerings market. |
Catalent | They compete in the mRNA offerings market. |
Samsung Biologics | They compete in the mRNA offerings market. |
Integrated DNA Technologies | They serve less complex customer needs in the custom oligonucleotide space. |
EMD Millipore Corporation (Millipore Sigma) | They serve less complex customer needs in the custom oligonucleotide space and compete in the oligonucleotide synthesis inputs market as large distributor-manufacturers. |
LGC Biosearch Technologies | They serve more complex customer needs in the custom oligonucleotide space. |
GenScript Biotech Corporation | They serve more complex customer needs in the custom oligonucleotide space. |
They compete in the specialty enzymes offering. | |
Roche | They compete in the specialty enzymes offering. |
BioGenes | They compete against other bioprocess impurity kit providers for drugs in early development and are main competitors in custom assay development. |
Enzo Life Sciences | They compete against other bioprocess impurity kit providers for drugs in early development. |
Rockland Immunochemicals | They are main competitors in custom assay development. |
Customer | Relationship | Segment | Details |
---|---|---|---|
Nacalai USA, Inc. | Major customer purchasing nucleic acid products | Nucleic Acid Production | 20.8% of 2024 revenue (~$53.3M) , 19.3% of 2023 revenue (~$55.6M) , 36.8% of 2024 accounts receivable (~$14.2M) , 27.3% of 2023 AR |
CureVac N.V. | Major customer with significant AR concentration | Nucleic Acid Production | 13.0% of 2023 accounts receivable |
BioNTech SE | Major customer purchasing nucleic acid products in 2022 | Nucleic Acid Production | 34.8% of 2022 revenue |
Pfizer Inc. | Major customer purchasing nucleic acid products in 2022 | Nucleic Acid Production | 26.4% of 2022 revenue |
Notable M&A activity and strategic investments in the past 3 years.
Company | Year | Details |
---|---|---|
Molecular Assemblies, Inc. | 2025 | Maravai LifeSciences acquired assets and intellectual property from Molecular Assemblies, Inc. in January 2025 for $11.5 million (subject to customary post-closing adjustments) to expand its capabilities in next-generation mRNA and CRISPR nucleic acid therapies. |
Officinae Bio, S.R.L. | 2025 | In February 2025, Maravai LifeSciences completed the acquisition of Officinae Bio’s DNA and RNA business for a base price of $10.0 million with up to $35.0 million in contingent payments, leveraging its AI- and ML-powered digital platform to enhance its nucleic acid production business. |
Alphazyme, LLC | 2023 | On January 18, 2023, Maravai LifeSciences acquired Alphazyme, LLC for a total consideration of $75.3 million (comprising $70.1 million in cash and $5.3 million in contingent consideration), thereby expanding its enzyme portfolio and strengthening its mRNA manufacturing services. |
MyChem, LLC | 2022 | Maravai LifeSciences acquired MyChem, LLC on January 27, 2022, for a total purchase price of $257.8 million (including $240.0 million in cash at closing and up to $60.0 million contingent earn-out), with the aim to vertically integrate its supply chain and enhance its offerings for therapeutics and vaccines. |
No recent press releases or 8-K filings found for MRVI.